CAS: 3871-20-3; Tris(4-Nitrophenyl) Phosphate

上下游产品

CAS号100-02-7 对硝基苯酚 | CAS号777-52-6 4-硝基苯二氯化磷 | CAS号115-86-6 磷酸三苯酯 | CAS号28341-54-0 4-(4-硝基苯氧基)丁酸 | CAS号824-78-2 4-硝基苯酚钠 | CAS号64131-85-7 Phosphorothioic... | CAS号1124-31-8 对硝基(苯)酚钾 | CAS号7697-37-2 硝酸 | CAS号49562-76-7 4-硝基苯辛醚 | CAS号950-35-6 甲基对氧磷 | CAS号512-56-1 磷酸三甲酯 | CAS号799-87-1 methyl bis(4-ni... | CAS号78-40-0 磷酸三乙酯 | CAS号645-15-8 双(对硝基苯基)磷酸酯 | CAS号1145-76-2 1-苄氧基-4-硝基苯 | CAS号14609-74-6 Phenol, 4-nitro... | CAS号7279-71-2 bis(4-nitrophen...

📜对硝基苯酚置于sodium Methylate,三氯氧磷体系中,用 甲醇,甲苯 作为反应溶剂,化学反应生成 三(4-硝基苯基)磷酸酯
参考文献:使用反应量热法评价磷酸三芳基酯合成的动力学参数
标题:使用反应量热法评价磷酸三芳基酯合成的动力学参数
摘要:磷酸三芳基酯是通过"一锅法"通过酚钠与三氯氧磷反应制备的.该系统可以描述为半间歇反应,其中酚盐在反应器内合成,并通过泵连续加入三氯氧磷的甲苯溶液.这些高放热反应在 Mettler Rc-1 反应量热仪中进行.这项工作的目的是通过研究放热速率来评估反应速率和反应速率常数.尽管酚盐几乎立即与磷酰氯反应,但可以注意到所研究的酚钠之间的细微差别.带有给电子基团(甲氧基)的酚盐反应性最强,带有吸电子基团(硝基)的那个是最不活泼的.可以认为反应是进料控制的.结果表明,反应温度不影响反应...
DOI:10.1021/op025554W

专利信息

专利号:US-10266565-B2
优先权日:2011-04-12
标 题 :Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
发明人：BURKE JR TERRENCE R; LIU FA; LEE KYUNG S; PARK JUNG-EUN
权利人:BURKE JR TERRENCE R; LIU FA; LEE KYUNG S; PARK JUNG EUN; THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
摘要:Novel compounds are provided that bind to polo-like kinases through the polo-box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo-like kinases through the polo-box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds.

专利号:WO-2025217610-A1
优先权日:2024-04-12
标题:Systems and methods for enzymatic oligonucleotide synthesis
发明人：ENTWISTLE DAVID; GAUNTLETT DEREK; MILLER MICHAEL; REEVES RYAN; WATTS DAVID
权利人:CODEXIS INC
摘要:The present invention provides for methods and systems for template-free synthesis of an oligonucleotide, and methods of using the systems as disclosed herein for template-free synthesis of an oligonucleotide.

专利号:US-6376475-B1
优先权日:1997-05-30
标 题 :Control of immune responses by modulating activity of glycosyltransferases
发明人：MARTH JAMEY D; PAULSON JAMES C
权利人:ABARON BIOSCIENCES INC; UNIV CALIFORNIA
摘要:The invention provides methods for inhibiting immune responses by inhibiting the biosynthesis of the sialyl galactosides that are involved in immune responses. In particular, B lymphocyte-mediated immune responses are mediated by interfering with synthesis of α2,6 sialylgalactosides, while T lymphocyte-mediated immune responses are inhibited by blocking synthesis of α2,3 sialylgalactosides. The inhibition is accomplished by, for example, inhibiting the activity of a glycosyltransferase involved in synthesis of the respective sialyl galactoside.

专利号:US-6225329-B1
优先权日:1998-03-12
标 题 :Modulators of protein tyrosine phosphatases (PTPases)
发明人：RICHTER LUTZ STEFAN; ANDERSEN HENRIK SUNE; VAGNER JOSEF; JEPPESEN CLAUS BEKKER; MOELLER NIELS PETER HUNDAHL; BRANNER SVEN; SU JING; BAKIR FARID; JUDGE LUKE MILBURN
权利人:NOVO NORDISK AS
摘要:The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like, n wherein A, R 1 , R 2 , R 3 , R 4 , R 16 and R 17 are as defined in the specification. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

专利号:US-6117974-A
优先权日:1991-10-02
标题:Libraries of backbone-cyclized peptidomimetics
发明人：GILON CHAIM; HORNIK VERED
权利人:PEPTOR LTD; YISSUM RES DEV CO
摘要:Libraries of novel backbone-cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units used in the synthesis of these backbone-cyclized peptide analogs are N(((-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N(((-functionalized) amino acids are incorporated into a library of peptide sequences, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by libraries of backbone-cyclized bradykinin analogs, somatostatin analogs, BPI analogs and Substance P analogs having biological activity. Further embodiments of the invention are Interleukin-6 receptor derived peptides having ring structures involving backbone cyclization.

专利号:US-2005119332-A1
优先权日:1998-03-12
标 题 :Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
发明人：JEPPESEN LONE; ANDERSEN HENRIK S; OLSEN OLE H; JUDGE LUKE M; HOLSWORTH DANIEL D; BAKIR FARID; AXE FRANK U; GE YU
摘要:The present invention provides novel compounds of formula 1a, n nnovel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.